Shares of Astrana Health, Inc. (NASDAQ:ASTH – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $47.8571.
ASTH has been the subject of several analyst reports. TD Cowen increased their target price on shares of Astrana Health from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Robert W. Baird set a $45.00 price target on shares of Astrana Health in a report on Friday, May 8th. Truist Financial upped their price target on shares of Astrana Health from $38.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, May 14th. BTIG Research increased their price objective on shares of Astrana Health from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Tuesday, July 14th. Finally, Barclays upgraded shares of Astrana Health from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $37.00 to $50.00 in a research report on Tuesday, May 26th.
Get Our Latest Analysis on ASTH
Institutional Investors Weigh In On Astrana Health
Astrana Health Stock Performance
Shares of ASTH opened at $40.31 on Friday. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 1.20. The business has a 50-day simple moving average of $41.78 and a two-hundred day simple moving average of $31.87. The stock has a market cap of $2.25 billion, a price-to-earnings ratio of 66.08 and a beta of 0.89. Astrana Health has a 52 week low of $18.08 and a 52 week high of $51.60.
Astrana Health (NASDAQ:ASTH – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.74 EPS for the quarter, topping the consensus estimate of $0.29 by $0.45. The firm had revenue of $965.10 million for the quarter, compared to the consensus estimate of $949.21 million. Astrana Health had a return on equity of 9.22% and a net margin of 0.86%.The business’s revenue for the quarter was up 55.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.42 earnings per share. On average, analysts expect that Astrana Health will post 1.25 EPS for the current year.
Astrana Health Company Profile
Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.
See Also
- Five stocks we like better than Astrana Health
- AMD and Cerbras Create A New Blueprint For Hardware
- Intel Earnings Reveal Whether the Chip Selloff Created a Buy
- CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test
- Plugging In: How Kinder Morgan Powers Up Profits
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.
